Cantel Medical Corp. (NYSE:CMD) has earned a consensus broker rating score of 2.25 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. Cantel Medical’s rating score has improved by 10% from three months ago as a result of various analysts’ ratings changes.
Analysts have set a 1-year consensus price target of $115.00 for the company and are anticipating that the company will post $0.58 EPS for the current quarter, according to Zacks. Zacks has also given Cantel Medical an industry rank of 163 out of 265 based on the ratings given to its competitors.
Cantel Medical (CMD) traded up $0.40 on Friday, hitting $111.51. 136,466 shares of the company traded hands, compared to its average volume of 111,873. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.48 and a current ratio of 2.44. Cantel Medical has a 1 year low of $69.21 and a 1 year high of $111.73. The firm has a market cap of $4,606.17, a PE ratio of 61.61 and a beta of 1.25.
Cantel Medical (NYSE:CMD) last posted its earnings results on Thursday, December 7th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.05. Cantel Medical had a net margin of 9.50% and a return on equity of 17.42%. analysts forecast that Cantel Medical will post 2.35 earnings per share for the current fiscal year.
The company also recently announced a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Investors of record on Wednesday, January 17th will be paid a $0.085 dividend. This is a boost from Cantel Medical’s previous Semi-Annual dividend of $0.07. This represents a dividend yield of 0.17%. The ex-dividend date is Tuesday, January 16th. Cantel Medical’s payout ratio is currently 7.73%.
In related news, EVP Eric W. Nodiff sold 2,868 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $97.55, for a total value of $279,773.40. Following the completion of the transaction, the executive vice president now directly owns 39,102 shares in the company, valued at approximately $3,814,400.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 12.30% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC acquired a new position in Cantel Medical during the second quarter worth $4,820,000. Koch Industries Inc. acquired a new position in Cantel Medical during the second quarter worth $407,000. Goldman Sachs Group Inc. acquired a new position in Cantel Medical during the second quarter worth $6,076,000. State Street Corp acquired a new position in Cantel Medical during the second quarter worth $72,607,000. Finally, Stifel Financial Corp acquired a new position in Cantel Medical during the second quarter worth $13,303,000. Hedge funds and other institutional investors own 85.20% of the company’s stock.
About Cantel Medical
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.